カテゴリ： GlobalData, アメリカ, 企業調査

ContraVir Pharmaceuticals Inc (CTRV)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：ContraVir Pharmaceuticals Inc (CTRV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8298
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：62
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
ContraVir Pharmaceuticals Inc (ContraVir) is a biopharmaceutical company that offers development and commercialization of targeted antiviral therapies. The company provides pipeline product such as TXL, potent prodrug of antiviral tenofovir and CRV431 cyclophilin inhibitor that increases its potency and selective index against HBV. It products are used for the treatment of chronic hepatitis B and shingles. ContraVir serves atients and healthcare professionals by developing differentiated therapeutic products. The company operates in the US. ContraVir is headquartered in Edison, New Jersey, the US.

ContraVir Pharmaceuticals Inc (CTRV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Ciclofilin Pharma Acquires NICAMs Assets from Aurinia Pharma 11
Venture Financing 12
Ciclofilin Pharma Raises USD0.05 Million in Venture Financing 12
Partnerships 13
ContraVir Pharma Enters into Agreement with Li Ka Shing Institute of Virology 13
Center Point Clinical Services Enters into Agreement with ContraVir Pharma 14
Licensing Agreements 15
Chimerix Enters into Licensing Agreement with ContraVir Pharma for CMX157 15
Equity Offering 17
ContraVir Pharma to Raise USD10.8 Million Rights Offering of Shares 17
ContraVir Pharma Raises up to USD13.6 Million in Public Offering of Shares 18
ContraVir Pharma Raises USD7 Million in Public Offering of Shares and Warrants 19
ContraVir Pharma Raises USD15 Million in Public Offering of Shares and Warrants 20
ContraVir Pharma Raises USD9 Million in Private Placement of Preferred Shares 22
ContraVir Pharma Spin Off from Synergy Pharma 23
ContraVir Pharma Completes Private Placement Of Securities For US$3 Million 24
Debt Offering 25
ContraVir Pharma Raises USD3.3 Million in Private Placement of 10% Notes Due 2019 25
Acquisition 26
ContraVir Pharma Acquires Ciclofilin Pharma 26
ContraVir Pharmaceuticals Inc – Key Competitors 27
ContraVir Pharmaceuticals Inc – Key Employees 28
ContraVir Pharmaceuticals Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Corporate Communications 30
Oct 03, 2018: ContraVir Pharmaceuticals names Robert Foster as acting Chief Executive Officer 30
Jun 20, 2018: ContraVir Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements 31
Apr 09, 2018: ContraVir Pharmaceuticals Appoints Two New Hepatitis B Experts to Scientific Advisory Board 32
Feb 05, 2018: Contravir Pharmaceuticals Receives Positive Nasdaq Listing Determination 33
Dec 29, 2017: ContraVir Pharmaceuticals Announces John Sullivan-Bolyai, M.D., MPH Steps Down as Chief Medical Officer 34
Product News 35
11/27/2017: ContraVir Pharmaceuticals to Make Presentation on CRV431 at HEP DART 2017 35
11/27/2017: ContraVir Pharmaceuticals to Make Presentations at HEP DART 2017 36
10/12/2017: ContraVir Pharmaceuticals to Present Poster on CMX-157 at AASLD 2017 and Participate in Search for HBV / HDV Cure Analyst Day 37
10/12/2017: ContraVir Pharmaceuticals to Present two Posters on CRV-431 at AASLD 2017 38
09/19/2017: ContraVir Pharmaceuticals Announces Participation at the Discovery on Target 2017 Conference in Boston 39
09/11/2017: ContraVir Pharmaceuticals Receives HBV IND Approval for Tenofovir Exalidex in the United States 40
09/06/2017: ContraVir Pharmaceuticals Announces Acceptance of Clinical Trial Application in the United Kingdom 41
05/04/2017: ContraVir to Advance Second-Generation Formulation of Tenofovir Exalidex for Treatment of Hepatitis B Virus 42
04/22/2017: Data Enhances Understanding of ContraVir’s Complementary Anti-HBV Compounds Tenofovir Exalidex and CRV431 43
04/12/2018: ContraVir Pharmaceuticals Announces New Data Presented at the 2018 International Liver Congress 44
04/11/2017: ContraVir to Highlight New Data on Tenofovir Exalidex at EASL The International Liver Congress 2017 in Amsterdam, The Netherlands 46
04/11/2017: ContraVir to Present Data on CRV431 at EASL The International Liver Congress 2017 in Amsterdam, The Netherlands 47
04/04/2017: ContraVir’s Cyclophilin Inhibitor CRV431 Targets Hepatitis B Surface Antigen (HBsAg) 48
04/03/2018: ContraVir Pharmaceuticals to Present On its HBV Drug Candidate CMX-157 at the 53rd Annual International Liver Congress 49
04/03/2018: ContraVir Pharmaceuticals to Present On its HBV Drug Candidate CRV-431 at the 53rd Annual International Liver Congress 50
01/03/2017: ContraVir Awarded Grant from Canada’s National Research Council to Advance CRV431 for the Treatment of Hepatitis B 51
Product Approvals 52
Feb 22, 2018: ContraVir Pharmaceuticals Announces TXL Has Been Granted Orphan Drug Designation for the Treatment of HBV in a Pediatric Population 52
Feb 12, 2018: ContraVir Pharmaceuticals Reaches Agreement with the FDA on the NDA Package for TXL Leveraging the 505(b)(2) Regulatory Pathway 53
Clinical Trials 54
Feb 06, 2018: ContraVir Pharmaceuticals Completes Renal Impairment Study with TXL 54
Oct 24, 2017: ContraVir Pharmaceuticals Announces National Institutes of Health Funded Study on Antiviral Activity of CRV431 55
Oct 19, 2017: ContraVir Pharmaceuticals Initiated Dosing of Renally-Impaired Patients in First U.S. Trial with TXL 56
Aug 08, 2017: ContraVir Pharmaceuticals Selected to Present Poster on TXL at the Upcoming AASLD Meeting 2017 57
Aug 03, 2017: ContraVir Pharmaceuticals Selected to Present Two Posters on CRV431 at the Upcoming AASLD Meeting 2017 58
Apr 20, 2017: Oral Presentation at EASL Highlights ContraVir’s Tenofovir Exalidex Antiviral Activity in Hepatitis B Patients 59
Feb 14, 2017: ContraVir to Highlight Clinical Data from Ongoing Phase 2a Study of Tenofovir Exalidex for Treating Hepatitis B 60
Other Significant Developments 61
Aug 06, 2018: Contravir Pharmaceuticals provides an update to corporate objective 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ContraVir Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ciclofilin Pharma Acquires NICAMs Assets from Aurinia Pharma 11
Ciclofilin Pharma Raises USD0.05 Million in Venture Financing 12
ContraVir Pharma Enters into Agreement with Li Ka Shing Institute of Virology 13
Center Point Clinical Services Enters into Agreement with ContraVir Pharma 14
Chimerix Enters into Licensing Agreement with ContraVir Pharma for CMX157 15
ContraVir Pharma to Raise USD10.8 Million Rights Offering of Shares 17
ContraVir Pharma Raises up to USD13.6 Million in Public Offering of Shares 18
ContraVir Pharma Raises USD7 Million in Public Offering of Shares and Warrants 19
ContraVir Pharma Raises USD15 Million in Public Offering of Shares and Warrants 20
ContraVir Pharma Raises USD9 Million in Private Placement of Preferred Shares 22
ContraVir Pharma Spin Off from Synergy Pharma 23
ContraVir Pharma Completes Private Placement Of Securities For US$3 Million 24
ContraVir Pharma Raises USD3.3 Million in Private Placement of 10% Notes Due 2019 25
ContraVir Pharma Acquires Ciclofilin Pharma 26
ContraVir Pharmaceuticals Inc, Key Competitors 27
ContraVir Pharmaceuticals Inc, Key Employees 28
ContraVir Pharmaceuticals Inc, Other Locations 29
ContraVir Pharmaceuticals Inc, Subsidiaries 29

List of Figures
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[ContraVir Pharmaceuticals Inc (CTRV)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Herantis Pharma Plc (HRTIS)：医療機器：M&Aディール及び事業提携情報
    Summary Herantis Pharma Plc (Herantis Pharma) is a drug development company that offers regenerative medicine for neurodegenerative diseases. The company's pipeline products include CDNF for amyotrophic lateral sclerosis, CDNF for Parkinson’s disease and lymfactin for secondary lymphedema. Its lymfa …
  • Britannia Pharmaceuticals Ltd：企業の戦略的SWOT分析
    Britannia Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Chattem Inc：企業の戦略・SWOT・財務情報
    Chattem Inc - Strategy, SWOT and Corporate Finance Report Summary Chattem Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Salzgitter AG：企業の戦略・SWOT・財務分析
    Salzgitter AG - Strategy, SWOT and Corporate Finance Report Summary Salzgitter AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Mesa Air Group, Inc.：企業の戦略・SWOT・財務分析
    Mesa Air Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Mesa Air Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Perma-Fix Environmental Services, Inc. (PESI)：企業の財務・戦略的SWOT分析
    Perma-Fix Environmental Services, Inc. (PESI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • SMART Technologies Inc.：企業の戦略的SWOT分析
    SMART Technologies Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Henry Schein Inc (HSIC)：医療機器：M&Aディール及び事業提携情報
    Summary Henry Schein Inc (Henry Schein) is a distributor of medical, dental and veterinary products including vaccines, medicines and equipment. Its product portfolio consists of dental, medical and animal health products, software and technology and other value-added services, besides financial ser …
  • Oman Air (SAOC)：企業の戦略・SWOT・財務情報
    Oman Air (SAOC) - Strategy, SWOT and Corporate Finance Report Summary Oman Air (SAOC) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Ann Inc：企業の戦略的SWOT分析
    Ann Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • West Japan Railway Co (9021)：企業の財務・戦略的SWOT分析
    West Japan Railway Co (9021) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Covalon Technologies Ltd (COV)-製薬・医療分野：企業M&A・提携分析
    Summary Covalon Technologies Ltd (Covalon) is a researcher, developer and commercialization of medical devices and healthcare technologies. The company offers advanced wound solutions, infection prevention products and perioperative care products. Covalon offers wound care products such as collagen …
  • Adenovir Pharma AB-製薬・医療分野：企業M&A・提携分析
    Summary Adenovir Pharma AB (Adenovir Pharma) is a drug development company that develops antiviral medicinal solutions for the treatment of infectious diseases such as adenoviral conjunctivitis and epidemic keratoconjunctivitis affecting the eyes. The company’s products are eye drops which acts outs …
  • Abbott Molecular Inc-医療機器分野：企業M&A・提携分析
    Summary Abbott Molecular Inc (Abbott Molecular), a subsidiary of Abbott Laboratories is a medical diagnostic company that provides molecular testing solutions. The company’s products include infectious disease products, oncology products, genetics products, automation products, molecular diagnostics …
  • Goa Shipyard Ltd：企業の戦略・SWOT・財務分析
    Goa Shipyard Ltd - Strategy, SWOT and Corporate Finance Report Summary Goa Shipyard Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Buongiorno SpA：企業の戦略的SWOT分析
    Buongiorno SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Ambu AS (AMBU B)：企業の財務・戦略的SWOT分析
    Ambu AS (AMBU B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Argonaut Gold Inc.：企業の戦略・SWOT・財務情報
    Argonaut Gold Inc. - Strategy, SWOT and Corporate Finance Report Summary Argonaut Gold Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Canada Bread Company, Limited：企業の戦略・SWOT・財務情報
    Canada Bread Company, Limited - Strategy, SWOT and Corporate Finance Report Summary Canada Bread Company, Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Jadason Enterprises Ltd (J03)：企業の財務・戦略的SWOT分析
    Jadason Enterprises Ltd (J03) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆